abiraterone acetate Zentiva

Abiraterone acetate Zentiva is a generic formulation of abiraterone acetate, an orally active inhibitor of the sterol 17α-hydroxylase/C17,20-lyase (CYP17A1) enzyme complex. By inhibiting CYP17A1, the drug blocks the biosynthesis of androgens in the testes, adrenal glands, and prostate tumor tissues, which is critical for the progression of hormone-sensitive and castration-resistant prostate cancer. Developed by Zentiva, this specific formulation has been evaluated in pharmacokinetic studies to compare immediate-release prototypes against reference products. It is typically administered in combination with prednisone or prednisolone for the treatment of metastatic prostate cancer.

Brand names

Abiraterone acetate Zentiva

Other names

abiraterone acetate